These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21168618)

  • 41. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
    Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
    Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
    Bakr MA; Gheith OA; Ismael AM; Baz ME; Shehab El-Dein AB; Ghoneim MA
    Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors.
    Sánchez-Fructuoso AI; Marques M; Conesa J; Ridao N; Rodríguez A; Blanco J; Barrientos A
    Transpl Int; 2005 May; 18(5):596-603. PubMed ID: 15819810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
    Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
    Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
    J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Revival of effective and safe high-dose mizoribine for the kidney transplantation.
    Sugitani A; Kitada H; Ota M; Yoshida J; Doi A; Hirakata H; Tanaka M
    Clin Transplant; 2006; 20(5):590-5. PubMed ID: 16968484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients.
    Cibrik D; Meier-Kriesche HU; Bresnahan B; Wu YM; Klintmalm G; Kew CE; Kuo PC; Whelchel J; Cohen D; Baliga P; Akalin E; Benedetti E; Wright F; Lieberman B; Ulbricht B; Jensik S;
    Clin Transplant; 2007; 21(2):192-201. PubMed ID: 17425744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Japanese multicenter study of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroid in renal transplantation (the fourth report).
    Oshiro Y; Nakagawa K; Hoshinaga K; Aikawa A; Shishido S; Yoshida K; Asano T; Murai M; Hasegawa A
    Transplant Proc; 2013 May; 45(4):1476-80. PubMed ID: 23726601
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study.
    Cabello M; García P; González-Molina M; Díez de los Rios MJ; García-Sáiz M; Gutiérrez C; López V; Sola E; Burgos D; Hernández D
    Transplant Proc; 2010 Oct; 42(8):3038-40. PubMed ID: 20970603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report.
    Shapiro R; Jordan ML; Scantlebury VP; Vivas C; Gritsch HA; Casavilla FA; McCauley J; Johnston JR; Randhawa P; Irish W; Hakala TR; Fung JJ; Starzl TE
    J Urol; 1998 Dec; 160(6 Pt 1):1982-5; discussion 1985-6. PubMed ID: 9817305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation.
    Busque S; Shoker A; Landsberg D; McAlister V; Halloran P; Shapiro J; Peets J; Schulz M
    Transplant Proc; 2001; 33(1-2):1266-7. PubMed ID: 11267285
    [No Abstract]   [Full Text] [Related]  

  • 54. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years.
    Kumar MS; Heifets M; Moritz MJ; Saeed MI; Khan SM; Fyfe B; Sustento-Riodeca N; Daniel JN; Kumar A
    Transplantation; 2006 Mar; 81(6):832-9. PubMed ID: 16570004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of EQUORAL in de novo renal transplant recipients.
    Zadrazil J; Jabry SA; Bachleda P; Gibejová A
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Dec; 148(2):171-3. PubMed ID: 15744368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of initial exposure to calcineurin inhibitors on kidney graft function of patients at high risk to develop delayed graft function.
    Silva LA; Felipe CR; Park SI; Pinheiro-Machado P; Garcia R; Franco M; Moreira SR; Tedesco-Silva H; Medina-Pestana J
    Braz J Med Biol Res; 2006 Jan; 39(1):43-52. PubMed ID: 16400463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety.
    Ju MK; Huh KH; Park KT; Kim SJ; Cho BH; Kim CD; So BJ; Kang CM; Lee S; Joo DJ; Kim YS
    Transplant Proc; 2013 May; 45(4):1481-6. PubMed ID: 23726602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Withdrawal of steroids from triple-drug therapy in kidney transplant patients.
    Matl I; Lácha J; Lodererová A; Símová M; Teplan V; Lánská V; Vítko S
    Nephrol Dial Transplant; 2000 Jul; 15(7):1041-5. PubMed ID: 10862645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The 4-week serum creatinine level predicts long-term renal dysfunction after adult living donor liver transplantation.
    Lin YH; Lin CC; Wang CC; Wang SH; Liu YW; Yong CC; Lin TL; Li WF; Concejero AM; Chen CL
    Transplant Proc; 2012 Apr; 44(3):772-5. PubMed ID: 22483492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients.
    Khwaja K; Asolati M; Harmon J; Melancon JK; Dunn T; Gillingham K; Kandaswamy R; Humar A; Gruessner R; Payne W; Najarian J; Dunn D; Sutherland D; Matas AJ
    Am J Transplant; 2004 Jun; 4(6):980-7. PubMed ID: 15147433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.